Innovation for Good Health

FOSUN PHARMA
Board of Directors 05
About Fosun Pharma 06
Brand Ideology 08
Global Strategy 09
Research and Development 10
Products and Services 12
Pursuit of Excellence 18
Marketing and Sales Network 19
Management Team 20
Optimized Management and Integrated Resources 24
Standardized Governance and Shared Development 25
Corporate Culture and Social Responsibility 26
Milestones 30

■ All data according to A shares financial statement of Fosun Pharma
Fosun Pharma will continue to strengthen its innovation capability, service quality, integration ability and internationalization level through efficient operation, investment and management of excellent enterprises in the industry, so as to become the industry leader of healthcare products and services.

Our vision is to become the first-tier enterprise in the global mainstream pharmaceutical and healthcare market.
Zhang Guozheng  
Non-executive Director of Fosun Pharma

Guo Guangchang  
Non-executive Director of Fosun Pharma

Chen Qiyu  
Executive Director and Chairman of the Board of Fosun Pharma

Wang Qunbin  
Non-executive Director of Fosun Pharma

Yao Fang  
Executive Director, Vice Chairman of the Board and Chief Executive Officer of Fosun Pharma

Guo Guangchang  
Non-executive Director of Fosun Pharma

Zhang Guozheng  
Non-executive Director of Fosun Pharma
Fosun Pharma is dedicated to becoming the first-tier enterprise in the global mainstream pharmaceutical and healthcare market by taking the mission of caring for the health of people and striving to implement the enterprise’s spirit of "Self-improvement, Teamwork, Performance and Contribution to Society".

Chen Qiyu

Fosun Pharma sticks to the concept of "Innovation for Good Health" and persists in product innovation and management enhancement, and is developing the pharmaceutical and healthcare business for purposes of becoming one of the most sustainably developed enterprises in the mainstream pharmaceutical and healthcare market by endeavouring its best efforts to offering quality products and superb service.

Yao Fang
Since it listed in 1998, Fosun Pharma’s net profits have increased 28 times in the past 15 years with a CAGR of 52%.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma") is a leading healthcare company in China. Established in 1994, Fosun Pharma has been listed on Shanghai Stock Exchange since August 1998 and on the Main Board of the Stock Exchange of Hong Kong Limited ("HKEx") (stock code: 600196-SH and 02196-HK) since October 2012.

Specializing in modern biopharmaceutical and healthcare industry, Fosun Pharma has captured opportunities within the rapidly developing Chinese healthcare industry as well as from the globalization of Chinese healthcare companies. Fosun Pharma's operations strategically cover several important segments of the healthcare industry value-chain such as pharmaceutical manufacturing, distribution and retail. In particular, Fosun Pharma has a leading market position in pharmaceutical distribution and retail, healthcare services, diagnostic products and medical devices, and maintains a strong focus on pharmaceutical R&D and manufacturing. As one of the largest healthcare companies in China, Fosun Pharma enjoys competitive advantages in R&D innovation, marketing, integration of mergers and acquisitions, as well as human resources development.

As a result of its focus on R&D innovation, Fosun Pharma maintains a highly capable international R&D team with operations in Shanghai, Chongqing and San Francisco in addition to its State-level Enterprise Technology Centre. Fosun Pharma's research and development activities focus on therapeutic areas such as cardiovascular, anti-tumor, central nervous system, metabolism and anti-infection.

In China, Fosun Pharma commands competitive advantages in the market segments of liver disease, diabetes, central nervous system, tuberculosis and in-vitro diagnostic products. Fosun Pharma is also the global market leader in anti-malarial drugs.

While focusing on pharmaceutical manufacturing, Fosun Pharma has built a leading position in diagnostic products and medical devices while actively developing its presence in healthcare services, where it has a solid foundation for domestic high-end and specialized medical services. Fosun Pharma is the second largest shareholder of Sinopharm, China's largest pharmaceutical distributor. The Company also operates leading local retail pharmacy chains such as For Me Pharmacy in Shanghai and Golden Elephant Pharmacy in Beijing. These distribution outlets provide Fosun Pharma with a nationwide retail pharmacy network.

Fosun Pharma believes in the principle of sustainable development and has incorporated social responsibility into its long-term business strategy. In full recognition of its social role, Fosun Pharma endeavors to meet the needs of its community, customers, employees and shareholders throughout the conduct of its business and planning for future development.

With its commitment to innovation for good health and creating a better future, Fosun Pharma stays focused on its mission to promote health and well-being of mankind.

Adhering to the model of a combination of organic growth, external expansion and integrated development, Fosun Pharma constantly strengthens its innovation capability, service quality, integration ability and internationalization capability. As a result, Fosun Pharma will emerge with an effective operation, world-class management, sound investments and as a leading provider of healthcare products and services.
Innovation for Good Health

Fosun Pharma is implementing its operating strategy of excellent brand portfolio from the healthcare industry and is thoroughly uplifting the value of the brand.

Brand Ideology
"Innovation for Good Health"—— continuous innovation, from the original inventions to the improvement of application skills, from the management optimization to the service innovation so as to yield more benefits for human health.
Combining China’s Growth Momentum with Global Resources

The strategic development model of Fosun Pharma is organic growth, external expansion and integrated development. That is to enhance the operating capability of the subsidiaries and to integrate the external resources to optimize the industrial chain. By integrating resources, enhancing its profitability and operating efficiency, Fosun Pharma has established competitive advantages in the industrial chain and become a leading company of healthcare products and services.

With an aim of going into the global mainstream market, Fosun Pharma utilizes the advantages of China’s market, resources and cost. Fosun Pharma has established the global marketing network and actively promote the integration of global pharmaceutical resources by strengthening globalization of pharmaceutical manufacturing, global R&D cooperation, product exportation, entrusted processing and conducting acquisition and merger.

With respect to the globalization of products and manufacturing, Fosun Pharma is promoting the international accreditation of the subsidiaries in order to facilitate its entry into the global market and become a part of the global pharmaceutical industrial chain. Fosun Pharma’s Artesunate series have passed WHO-PQ certification, which has solidified the company’s leading position in the anti-malaria market.

In October 2012, Fosun Pharma was successfully listed on the main board of Hong Kong Stock Exchange.

In 2013, Fosun Pharma acquired Alma Lasers Ltd., a world-leading Israeli aesthetic medical devices manufacturer, and captured the leading position in the corresponding international market segment. Fosun Pharma’s globalization prospect will see a bright future.
In 2012, the Company continued to improve R&D on generic and innovative drugs and the accumulated investment in R&D for the whole year amounted to RMB 370 million. Annual investment in R&D accounts for 7%-9% of the operating revenue of the pharmaceutical business.
R&D Platform

Highly Effective R&D System
Fosun Pharma has established a unique "4+1" R&D platform, which is aimed at hard-to-copy generics, small molecule chemical innovative drugs, large molecule biopharmaceutical drugs and specialized formulations. The Company continuously promotes R&D on generic drugs and innovative drugs and proactively follows the latest technological frontier of global pharmaceutical industry.

R&D Bases and Cooperation
Fosun Pharma creatively integrates domestic and overseas resources and constantly improves R&D. Fosun Pharma established "Strategic Alliance for Pharmaceutical Innovation" with top local academic research institutions, which is the one of the "Industrial Research Alliances", a major initiative of the national new-drug creation technology project. Fosun Pharma collaborates with Shanghai Institute of Pharmacology affiliated to Chinese Academy of Sciences develops a new model for innovative R&D. Fosun Pharma formed a joint venture with Dalian Wanchun to develop new anti-tumor drugs licensed with international properties. In 2012, construction of the Fosun Pharma Zhangjiang innovative R&D base was started, setting a solid foundation for the integrated platform for developing and piloting new drugs.

Fosun Pharma also actively utilizes international technology resources. It worked with Handa Pharmaceuticals of the United States and Lonza Group of Switzerland to jointly develop high-tech barrier drugs desperately needed in the Chinese market. A maturing R&D system has paved the way for sustainable brand development for Fosun Pharma.

R&D Team
Fosun Pharma’s R&D platform has attracted many top-notch scientists and talents from China as well as the United States. Currently, Fosun Pharma has 766 pharmaceutical R&D employees. The ratio of technical R&D staff within the group is 14.6%.

R&D Investment and Progress
In 2012, the Company continued to improve R&D on generic and innovative drugs and the accumulated investment in R&D for the whole year amounted to RMB 370 million. Annual investment in R&D accounts for 7%-9% of the operating revenue of the pharmaceutical business.

At present, over 100 R&D projects are being conducted, and 13 of them are being submitted for applying for the entry of clinical trial. Five projects are in the stage of clinical trial and 16 projects are pending for final approval.

In 2012, Fosun Pharma’s Pharmaceutical sector applied for 70 patents, of which 60 were utility patents. 33 patents have been granted, of which 28 were utility patents.
Fosun Pharma is persisting on the operating concept of "Innovation for good health", taking its core business in pharmaceutical field, keeping on product innovation and management enhancement and actively promoting and facilitating the strategy of "Organic Growth, External Expansion, and Integrated Development". Its main business has realized rapid growth. At present, the Company has 13 drugs or series with annual sale revenue exceeding RMB 100 Million.
Areas for Treatment and Key Products

<table>
<thead>
<tr>
<th>Areas for Treatment</th>
<th>Commodity Name</th>
<th>Common name / applications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolism and alimentary tract</td>
<td>Atomolan, Wan Su Lin, Wan Su Ping, Wanuric, Moluodan</td>
<td>Reduced Glutathione preparations, applicable for treatment of chronic Hepatitis B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Protamine Zinc Insulin Injection, used for treatment of Diabetes II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Glibempride Tablets, used for treatment of Diabetes II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fexibustat Tablets, used for chronic hyperuricemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stomach problems, including chronic atrophic gastritis, gastralgia and others</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Xin Xian An, Ke Yuan, Su Ke Nuo, You Di Er</td>
<td>Meglmune Adenosine Cyclphosphate Injection, for coronary artery heart disease, asystole, arrhythmia and sin sinus syndrome</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Calcium Dobesilate Capsules, used for prevention and treatment of diabetic retinopathy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Low Molecular Weight Heparin Sodium for Injection, used for preventing the formation of a blood clot during conducting Hemodialysis and the formation of deep venous thrombosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alprostadil Dried Emulsion for Injection, used to improve cardiovascular and cerebrovascular microcirculation and others</td>
</tr>
<tr>
<td>Blood system</td>
<td>Bang Ting, EPO</td>
<td>Hemocoagulase For Injection, used to reduce or stop bleeding</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Recombinant Human Erythropoietin (EPO) for Injection, used for anemia caused by malfunction of kidneys, including Hemodialysis Patients and Non-Hemodialysis Patients</td>
</tr>
<tr>
<td>Central nervous system</td>
<td>Ao De Jin, Qiwei</td>
<td>Deproteinised Calf Blood Serum Injection, used for improving such neurologic impairment caused by blood circulation in brain and Dystrophy (ischemic injury and craniocerebral trauma)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quetiapine Fumarate Tablets, used for curing positive and negative syndromes of schizophrenia</td>
</tr>
<tr>
<td>Anti-infective</td>
<td>ARTESUN-PLUS ARTESUN, Xi Chang, Shadoulika, Ethambutol Hydrochloride, Rifampicin</td>
<td>Artesunate preparations series, Artesun is recommended by WHO which is the first choice for the treatment of serious malaria of adults and children.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cefmetazole sodium for Injection, used for curing infectious diseases caused y several micro-organisms</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Potassium Sodium Pehydroandrographolide Succinate for Injection, mainly used for curing viral pneumonia and viral upper respiratory tract infection</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anti-tuberculosis series - Rifampicin and Isoniazid Tablets II, applicable for the intensified treatment of the first two months regarding short-term treatment of Tuberculosis and daily intake should be conducted for this stage</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Used for curing Tuberculosis and Infection by Enterococcus and etc.</td>
</tr>
<tr>
<td>Anti-tumor</td>
<td>Yi Luo Ze</td>
<td>Pemетодexed disodium for Injection is used for treatment of small-cell lung cancer and malignant pleural mesothelioma</td>
</tr>
</tbody>
</table>

In 2012, Fosun Pharma’s pharmaceutical manufacturing and R&D business recorded a revenue of RMB 4.68 billion, representing an increase of 20.98% compared with 2011, and segment operating profits of RMB 969.46 million, representing an increase of 29.92% compared with 2011.

Pharmaceutical industry is the core business of Fosun Pharma. The sales revenue and net profits of Aohong Pharmaceutical and Yao Pharma Co., Ltd., both of which are Fosun Pharma’s subsidiaries, recorded a significant increase in sales and net profit. According to IMS, Fosun Pharma is one of the top five domestic pharmaceutical companies in China. After several years of M&A, R&D and marketing promotion, 24 pharmaceutical subsidiaries have been established in 10 provinces, autonomous regions and municipalities nationwide under Fosun Pharma. The range of products covers metabolism and alimentary tract, cardiovascular, anti-tumor and immune regulation, central nervous system and anti-infection therapeutic areas. Among which, major products maintain leading position in the market. Currently, sales of 13 products have exceeded RMB 100 million per annum respectively. In 2012, Fosun Pharma provided the Chinese market with quality products that included approximately 300 million sterile preparation doses and 7 billion oral preparation pills/tablets. Fosun Pharma is also the global market leader in anti-malarial drugs.
Fosun Pharma enhanced the management and investment in medical service businesses. It has developed a business structure that comprises high-end hospital brand in coastal developed cities under the "United Family" brand and health services integrated system combining oncology specialty and general hospitals in second-and-third-tier cities.

In China, the "United Family" brand, with the highest brand popularity and the highest degree of internationalization, has become the first choice of health service brand for international high-caliber individuals in China. Jimin Cancer Hospital is the first cancer hospital in Anhui Province. In addition, the Yueyang Guangji Hospital and Suqian Zhongwu Hospital are tier-two general hospitals with good brand recognition locally. Guang Zhou Nan Yang Tumour Hospital was the earliest specialty hospital to adopt Integrated Chinese-Western therapy in China; Chancheng Hospital is a upper first-class hospital, which has significant influence in Foshan, Guangdong province and the whole Pearl River Delta.
Fosun Pharma's in-vitro diagnostics products cover clinical chemistry, clinical immunology, molecular diagnostics (gene-chip technology etc.), clinical microbiology, and embraces the superiority brands like "Long March" and "Yaneng". Fosun Pharma established a strategic partnership with Saladax Biomedical Inc. of the United States which owns the world-leading diagnostic technologies and chemotherapy treatment blood-monitoring products. As such, Fosun Pharma was granted the marketing and manufacturing rights of these products in China. Fosun Pharma also works with Korean company SD Biosensor to implement the rapid diagnostic technological platform in order to accelerate the full-scale development of its diagnostic business.

Jointly established by Fosun Pharma and Chindex International Inc., Chindex Medical Limited (CML) produces and sells medical devices, consumables, and premium medical devices as agent in China. As a leading medical devices supplier at present, CML has operational headquarters in both the US and China, and keeps overcoming regional and cultural restrictions to provide sophisticated medical technologies and high-quality products for the healthcare industry in China. In 2013, Fosun Pharma acquired Alma Lasers Ltd., a world-leading Israeli aesthetic medical devices manufacturer, and captured the leading position in the corresponding international market segment. Alma Lasers Ltd. has business in more than 60 countries and regions, including the United States, Germany and Brazil, and has 15% of the world’s market share in high-end aesthetic energy-based devices. The company entered China in 2003, and is now a market leader of high-end aesthetic medical devices provider in China.
Operating revenue in 2012 amounted to 

**RMB 135.8 billion**

Sinopharm Group has realized operating revenue of RMB 135.8 billion with the CAGR of 35% since 2003.

In 2003, Fosun and China National Pharmaceutical Group jointly founded the Sinopharm Group Co., Ltd, which was then listed on the Hong Kong Stock Exchange on September 23, 2009. Sinopharm is currently the largest distributor of pharmaceutical and healthcare products, as well as the leading supply-chain service provider in China. As a pharmaceutical distribution enterprise, it was ranked fourth in the world in terms of market value. In 2011, Sinopharm Group became "the first domestic enterprise with pharmaceutical distribution sales in excess of RMB 100 billion" and continues to maintain its position as a market leader.
Retail Pharmacies

660

By the end of 2012, there were more than 660 retail pharmacies under the company’s For Me Pharmacy and Golden Elephant Pharmacy brands.

Fosun Pharma keeps strengthening the development of pharmaceutical retail business. By the end of 2012, there were more than 660 retail pharmacies under the company’s For Me Pharmacy and Golden Elephant Pharmacy brands, which maintain leadership in their respective markets. They both are ranked first in terms of market share in Shanghai and Beijing pharmaceutical retail markets.
Fosun Pharma believes in strict quality control standards and procedures in pharmaceutical manufacturing, and commits to improve production standards and manufacturing procedures in accordance with latest international standards.

**EHS Management**

Fosun Pharma has been actively promoting the establishment of EHS management system, which supervises the workplace, occupational health and safety of the subsidiaries.

Fosun Pharma continues increasing its investment in environmental protection facilities and actively engages in charity affairs related to environmental protection. In 2012, the Company has invested almost RMB40 million into the reconstruction of environmental protection facilities. At present, six enterprises of Fosun Pharma have been approved by EHS system (GT/T24001-2004, GB/T28001-2001) and have been awarded the corresponding certificates regarding EHS.

---

**Active Pharmaceutical Ingredients Production Lines**

10

**Preparation Production Lines**

4

Have passed International GMP and other related certifications

Chongqing manufacturing base: On-site examination regarding active pharmaceutical ingredients approved by FDA, European EDQM, German Pharmaceutical Authority and Japanese Pharmaceutical Authority; the production line of solid preparations has obtained GMP certification from Canada Health Authority.

Guilin manufacturing base: Approved by WHO-PQ certification and being the designated supplier by WHO. Some workshops of active pharmaceutical ingredients are approved by FDA.

Xuzhou manufacturing base: has workshops in compliance with international GMP standard; Active pharmaceutical ingredients and preparations have passed GMP of new version.
Marketing Team

In order to optimize the allocation of resources, the Company continues expanding and strengthening the integration and development of the marketing system and has established a clinical specialists team with over 5,500 members in respect of pharmaceutical, diagnostics and devices consisting. The Company also focuses on clinical academic support in hospital, establishment of business channels and marketing promotion, in order to make the sales more professional, synergic and multi-layer.

Marketing Network

The sales channels of Fosun Pharma, with nearly 1,000 first-tier distributors, cover more than 30 provinces and cities in China. The distribution capability can reach the city and county level of pharmaceutical business in China. The Company is building a marketing network that can meet the need of drug consumption by all kinds of people. The Company is also gradually establishing a global marketing network wherein its products are exported to the U.S.A., Australia, Brazil, India and Africa and other countries and regions.
A team with entrepreneurship spirit has become one of the core competitiveness of Fosun Pharma’s development. Fosun Pharma and superb team of entrepreneurs jointly create values, share development and strive to build a globally competitive pharmaceutical enterprise.
A team with entrepreneurship spirit has become one of the core competitiveness of Fosun Pharma's development.
In order to build a globally competitive pharmaceutical enterprise, Fosun Pharma has transformed itself to follow market changes by earnestly executing its innovation strategy and optimizing its organizational structure. Through improving the corporate governance structure and promoting the entrepreneurial spirit, Fosun Pharma has nurtured a young, efficient and dynamic management team.

Today, Fosun Pharma has a team of international entrepreneurs from China, the U.S.A. Europe, Israel and other countries. They specialize in corporate operation and management and they are the company’s core competitiveness. Their entrepreneurial spirit and focus on innovative management concepts have helped the company optimize the management and standardized the operation.
Fosun Pharma actively conducts transformation to adapt to the market change, and promotes its new strategy and timely optimizing its organizational structure. It proves the management system in order to facilitate the overall highly efficient operation of the Company.

Pharmaceutical Management Committee, Pharmaceutical Commerce and Consumer Products Management Committee, Medical Care Management Committee and Medical Diagnostics Business Sector and Medical Devices Business Sector are established at the headquarters of the Group, among which, Pharmaceutical Management Committee is in charge of manufacturing and R&D of drugs and the platform and corporate function can be exercised through Fosun Pharmaceutical Industrial Development Company Limited, the subsidiary of Fosun Pharma, for purposes of conducting daily management and operation. With help of these three Committees and two Business sectors, a strategic controlling structure consisting of strategic planning system, operating plan and financial budget management system, and performance and incentive system have been established at Fosun Pharma’s headquarters. By doing so, highly effective and efficient operation are expected to be achieved for the Company.

For purposes of enhancing the efficiency of decision-making, Fosun Pharma has established a multi-department management committee in order to effectively prevent any risks caused by personal reasons.

---

**YaoPharma Co., Ltd.**

It is among the Top Three of the areas for liver diseases. Atomolan is the major product with annual sales of RMB1.325 billion in 2012. Sales growth and net profit have been increased by 397% since the investment made in 2012.

**Wanbang Pharmaceutical**

Biochemical insulin is in the first place by market share. With its annual sales of RMB1.011 billion in 2012, its sales growth and net profit have been increased by 522% and 150% respectively since the cooperation started with Fosun Pharma in 2004.

**Sinopharm**

With its annual sales of RMB135.787 billion in 2012, the net profit stood at RMB3.083 billion. During the 10-year cooperation, the CAGR of sales revenue and net profit are respectively 35% and 53%, which were much faster than the industry growth.
By the end of 2012, the shareholder’s equity increased by 2548.24%, when compared to that in 1998. The Company has distributed dividends for 13 consecutive years and the total tax payable was RMB789 million in 2012. Meanwhile, the Company continues to improve the remuneration and welfare system. For 2012, the Company paid more than RMB765 Million to employees in cash, which witnessed a growth of 22.17% when compared to that of 2011.

The Company has won the “8thGolden Round Table Best Award for Board of Directors”, “Top 10 Innovation Pharmaceutical Companies with Most Investment Value” and other awards.

### Fosun Pharma which is based on sincerity, actively creates value for the society and returns to shareholders.
Fosun Pharma believes that an enterprise should accomplish two reports: namely the Financial Report and Corporate Social Responsibility (CSR) Report. The Financial Report represents the achievement of an enterprise’s operation and performance of economic efficiency, while the CSR Report reflects the harmonious getting-along between the enterprise and the society, wherein all aspects in the enterprise can undertake a sustainable development.
Corporate spirit: “Self-improvement, Teamwork, Performance and Contribution to Society”. Fosun Pharma has always linked the belief: “to better oneself (self-improvement), to maintain social relationship and environment (Teamwork), to successfully establish the enterprise’s business (Performance) and to make contribution towards the homeland (Contribution to Society)” together.

Employee Development and Caring

The company has long been employing its corporate spirit since its foundation. Based on such spirit, Fosun Pharma has established the Corporate Culture Working Committee in order to promote the corporate culture, facilitate the harmonious development of the enterprise and strengthen the unity and competitive power of the corporate culture.

Fosun Pharma has proposed its view on talents by stating: “to attract talents by development, to provide a chance for talents to get together by business, to train talents by work and assess the talent by performance”. Fosun Pharma values the establishment of the talent pipeline and career development of staff, and stands firm to its talent management strategy of “pursuing the highly harmonious unification of personal success and enterprise development”. The internal promotion rate at Fosun Pharma’s headquarter has reached 20.6% in 2012.
Keep Improving the Charity System of “Future Star”

Fosun Pharma is acting on the principle of sustainable development and thus has placed the corporate social responsibility, economic effectiveness and ecological effectiveness in equally important positions. Since listed in Shanghai Stock Exchange market in 1998, Fosun Pharma has participated in and organized many charity activities in respect of education, research, environmental protection, health care, social needs and culture in many countries and regions.

At present, Fosun Pharma has set up a comprehensive charity system – “Future Star”, through which, it actively takes the corporate social responsibility by supporting the education, subsidizing scientific research, and social service for pharmaceutical health, remedying the sick and the orphans, donating to those who are in need of money and helping those who suffer from disasters. At present, more than two hundred excellent students and outstanding teachers are being subsidized. The Company assists in promoting the educational development in China and trains talents for the industry.

Since 2006, Fosun Pharma has long engaged in the development of China’s medical and health industry and actively supported Chinese government to provide foreign aid. Fosun Pharma has consecutively organized training on anti-malaria foreign aid of the Ministry of Commerce, and is highly appraised by the governments and trainees of the recipient countries. Meanwhile the Company has established volunteers team of Fosun Pharma, aiming at providing its employees with such charity platform and encouraging them to actively participate in social service and charity work.
Innovation for Good Health
Milestones

1994
Fosun Pharma predecessor – Shanghai Fosun Industrial Company Limited was established.

1998/8
Fosun Pharma predecessor – Shanghai Fosun Industrial Company Limited listed on the Shanghai Stock Exchange.

1999
The Company was recognized as the new high-tech enterprise at national level.

2003/1
Fosun and China National Pharmaceutical Group Corporation jointly established Sinopharm Group Company Limited.

2004/12
Fosun Industrial officially changed its name to Shanghai Fosun Pharmaceutical (Group) Company Limited.

2005/10
The Technology Center of Fosun Pharma was recognized as the state-level enterprise technology center.

2005/12
Fosun Pharma Artesunate became the first one that passed WHO’s recognition of the qualifications of direct supplier in China.

2007/8
Fosun Pharma’s Artesunate in combination was favored again by the WHO. Fosun Pharma became the global partnership of the WHO in the compound prescription of anti-malaria drug.

2005/4
Fosun Pharma was included in the CSI 300 Index, the SSE Dividend Index and the SSE Corporate Governance index.

2008/1
Fosun Pharma was recognized as a state-level innovative pilot enterprise.

2009/3
Chongqing Fochon Pharmaceutical Research Co., Ltd. was founded, initiating development of new patent medicines in the model of fast follower.

2009/9
Sinopharm Group Co., Ltd. jointly established by Fosun Pharma and China National Pharmaceutical Group Corp., was officially listed on the Main Board of HKEx.

2009/11
Wanbang Biopharmaceuticals Co., Ltd. and D-Pharm Ltd., an Israeli biotech company, signed a cooperation agreement regarding new products, which was the first time for a Chinese pharmaceutical company to be allowed to introduce new compounds of the USA for third stage of clinical treatment.

2009/12
Shanghai Henlius Biotech Co., Ltd. was established. It was dedicated to R & D and industrialization of macromolecular monoclonal antibodies, realizing parallel progress with globally leading biopharmaceutical technology.

2009/12
Fosun Pharma and Handan Moluodan Pharmaceutical Co. Ltd. officially signed an agreement to building a development platform which can better suit the modernized Chinese medicine industry.

2008/4 & 2012/6
Fosun Pharma was recognized as the Most Socially Responsible Corporate – Golden Bee Award twice.

2010/6
Fosun Pharma and Chindex International Inc. (hereinafter referred to as “Chindex”) signed a strategic alliance agreement and Fosun Pharma has become the first major shareholder of Chindex.

2010/12
Fosun Pharma announced in Shanghai that it would cooperate with Shenyang Hongqi Pharmaceutical Co., Ltd., the pioneer anti-tuberculosis enterprise in China. Both companies would jointly promote Chinese anti-tuberculosis drugs to enter into the global market.

2011
The original Fosun Pharma’s Medical Devices Business Department merged into Chinadex MRD business and became Chinadex Medical Limited.

2011/1
Fosun Pharmaceutical controlled the shareholding of Dalian Aleph Biomedical Co., Ltd. and took over vaccine business.

2011/3
Fosun Pharma was shortlisted in the list of “New Technological Enterprise” and was officially approved to be a “New Technological Enterprise”.

2011/8
Fosun Pharma controlled the shareholding of Jinzhou Aohong Pharmaceutical Co., Ltd. so as to further consolidate the pharmaceutical and biological manufacturing platform and enriching the structure of biological products.

2011/11
“2012 Report on Enterprise Social Responsibility was awarded with AA-grade. For three consecutive years, the Company was ranked No.1 in terms of the Report on Social Responsibility in pharmaceutical and biological manufacturing industry.

2012/10
Fosun Pharma was officially listed on the Hong Kong Stock Exchange and became the third pharmaceutical health company with dual listing of A-shares and H-share.

2012/11
Fosun Pharma built a new R&D base in Zhangjiang, Pudong District of Shanghai, so as to establish a world-class innovative pharmaceutical company.

2012/12
Fosun Pharma has worked jointly with Shanghai Institute of Materia Medica under Chinese Academy of Sciences and jointly developed 3 new targeted drugs for anti-tumor.

2012/11
Artesun-Plus manufactured by Guilin Pharma under Fosun Pharma passed the preliminary examination and verification conducted by WHO. It is also the Company’s sixth anti-malarial drug product that passed WHO-PQ.

2012/12
Fosun Pharma entered into the field of CNS (Central nervous system) drugs by acquiring Hunan Dongting Pharmaceutical Co., Ltd.

2012/12
Fosun Pharma and Suqian Zhongwu Hospital signed a cooperation agreement for purposes of continuing active development of medical service sector.

2013/4
Fosun Pharma acquired the globally leading medical and aesthetic device manufacturer--Israel-based Alma Lasers Ltd. for establishing a platform for R&D, manufacturing and management of the high-end medical devices.


For more details and information, please browse the website of Fosun Pharma

www.fosunpharma.com